Emil Lou, Professor with Tenure at University of Minnesota, shared a post on LinkedIn:
“I was pleased to collaborate with the Medscape Oncology team to provide some of my takes on updates and progress out of GI26, the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium that took place in January.
There was a lot to cover, including: next-generation strategies for targeting the pancreatic tumor microenvironment including using theranostics/radiopharmaceuticals, new IO options for upper GI cancers, and updates on effective use of ctDNA in colorectal cancers; and also addressing the rising tide of questions about GLP-1 agonists: any impact on cancer treatment?
ASCO GI: Practice-Changing Signals Across Pancreatic, Gastric, and Colorectal Cancers.”